NCT05524545 2025-07-25A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)ALX Oncology Inc.Phase 1 Completed36 enrolled
NCT02091999 2024-11-01A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4Astellas Pharma IncPhase 1 Completed213 enrolled
NCT03070990 2024-10-18A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaAstellas Pharma IncPhase 1 Completed19 enrolled
NCT01409135 2024-03-12A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4Astellas Pharma IncPhase 1 Completed34 enrolled